Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

The clinical efficacy of CRLX101, the nanoparticulate conjugate of cyclodextrin based polymer molecule and camptothecin is evaluated in patients with treatment refractory solid tumor malignancies by immunohistochemistry and pharmacogenomics. The decrease in expression of topoisomerase-1, Ki-67, CaIX, VEGF and CD31 after treatment with CRLX101 indicates inhibition of proliferation, hypoxia and angiogenesis correlating with slow tumor growth.594